Strategies for managing belantamab mafodotin-associated ocular toxicities
During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss strategies for managing belantamab mafodotin-associated ocular toxicities in patients with multiple myeloma (MM). The meeting featured a presentation by guest speaker Lisa Leypoldt, University Medical Center Hamburg-Eppendorf, followed by a faculty discussion on the practical challenges of monitoring, managing, and counseling patients receiving belantamab mafodotin-based therapies.
During their presentation, Leypoldt reviewed the mechanisms underlying belantamab mafodotin-associated…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.